AN

Ananda Pharma Plc

Develops approved cannabinoid medicines for pain, epilepsy, and heart failure.

ANAN | Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BDQPXQ60
LEI:
894500DFM8VOC5FW4X47
Country:
United Kingdom
Address:
6th Floor, 60 Gracechurch Street, EC3V 0HR London
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ananda Pharma Plc is a biopharmaceutical company focused on developing and commercializing regulatory-approved medicines derived from cannabinoids. The company targets complex conditions with significant unmet medical needs, primarily focusing on chronic inflammatory pain (including chemotherapy-induced peripheral neuropathy and endometriosis), drug-resistant epilepsies, and heart failure with preserved ejection fraction (HFpEF). Its integrated approach spans research, drug candidate development, clinical trials conducted with research partners, and navigating regulatory pathways for marketing authorization. Ananda Pharma leverages the well-understood safety profile of cannabinoids to potentially accelerate its clinical development programs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 08:20
Regulatory News Service
Confirmation of receipt of £168k R&D tax refund
English 23.0 KB
2025-10-13 15:45
Interim Report
Interims for the six months ended 31 July 2025
English 129.3 KB
2025-09-26 12:10
Legal Proceedings Report
Ananda ends UCL/GOSH trials, prioritises MRX1
English 22.6 KB
2025-09-16 08:00
Regulatory News Service
Ananda attending Cannabinoid Summit
English 22.1 KB
2025-08-26 15:43
Post-Annual General Meeting Information
Result of Annual General Meeting
English 29.6 KB
2025-08-19 08:00
Report Publication Announcement
Webinar Presentation Release
English 21.3 KB
2025-07-30 14:49
Pre-Annual General Meeting Information
Notice of Annual General Meeting
English 21.8 KB
2025-07-30 13:44
Report Publication Announcement
Publication of Annual Report
English 44.2 KB
2025-06-23 08:00
Regulatory News Service
Key Milestone in MRX1 Path to Clinical Trials
English 23.3 KB

Automate Your Workflow. Get a real-time feed of all Ananda Pharma Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ananda Pharma Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ananda Pharma Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NKMAX Co., Ltd. Logo
Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.
South Korea
182400
NLS Pharmaceutics Ltd. Logo
Developing therapies for rare CNS disorders, specializing in narcolepsy and sleep-wake issues.
United States of America
NLSP
NovaBay Pharmaceuticals, Inc. Logo
Develops clinically-proven anti-infective therapies for eyecare, skincare, and wound care.
United States of America
NBY
Novacyt Logo
Designs and supplies molecular diagnostic tests and PCR kits for human, veterinary, and food safety.
France
ALNOV
Novartis AG Logo
Develops and markets innovative medicines globally using advanced science and technology.
Switzerland
NOVN
NOVAVAX INC Logo
Develops and commercializes nanoparticle vaccines for serious infectious diseases.
United States of America
NVAX
Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.
South Korea
229500
Novo Nordisk Logo
Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.
Denmark
NOVO
NRX Pharmaceuticals, Inc. Logo
Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.
United States of America
NRXP
NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America
NCNA

Talk to a Data Expert

Have a question? We'll get back to you promptly.